Literature DB >> 14662768

Kinetic interaction analysis of human interleukin 5 receptor alpha mutants reveals a unique binding topology and charge distribution for cytokine recognition.

Tetsuya Ishino1, Gianfranco Pasut, Jeffery Scibek, Irwin Chaiken.   

Abstract

Human interleukin 5 receptor alpha (IL5Ralpha) comprises three fibronectin type III domains (D1, D2, and D3) in the extracellular region. Previous results have indicated that residues in the D1D2 domains are crucial for high affinity interaction with human interleukin 5 (IL5). Yet, it is the D2D3 domains that have sequence homology with the classic cytokine recognition motif that is generally assumed to be the minimum cytokine-recognizing unit. In the present study, we used kinetic interaction analysis of alanine-scanning mutational variants of IL5Ralpha to define the residues involved in IL5 recognition. Soluble forms of IL5Ralpha variants were expressed in S2 cells, selectively captured via their C-terminal V5 tag by anti-V5 tag antibody immobilized onto the sensor chip and examined for IL5 interaction by using a sandwich surface plasmon resonance biosensor method. Marked effects on the interaction kinetics were observed not only in D1 (Asp(55), Asp(56), and Glu(58)) and D2 (Lys(186) and Arg(188)) domains, but also in the D3 (Arg(297)) domain. Modeling of the tertiary structure of IL5Ralpha indicated that these binding residues fell into two clusters. The first cluster consists of D1 domain residues that form a negatively charged patch, whereas the second cluster consists of residues that form a positively charged patch at the interface of D2 and D3 domains. These results suggest that the IL5 x IL5Ralpha system adopts a unique binding topology, in which the cytokine is recognized by a D2D3 tandem domain combined with a D1 domain, to form an extended cytokine recognition interface.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14662768     DOI: 10.1074/jbc.M309327200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Asymmetric usage of antagonist charged residues drives interleukin-5 receptor recruitment but is insufficient for receptor activation.

Authors:  Tetsuya Ishino; Udaya Pillalamarri; Dominick Panarello; Madhushree Bhattacharya; Cecilia Urbina; Stephanie Horvat; Sanjay Sarkhel; Bradford Jameson; Irwin Chaiken
Journal:  Biochemistry       Date:  2006-01-31       Impact factor: 3.162

2.  Slow, reversible, coupled folding and binding of the spectrin tetramerization domain.

Authors:  S L Shammas; J M Rogers; S A Hill; J Clarke
Journal:  Biophys J       Date:  2012-11-20       Impact factor: 4.033

3.  Structural basis of interleukin-5 dimer recognition by its α receptor.

Authors:  Seisuke Kusano; Mutsuko Kukimoto-Niino; Nobumasa Hino; Noboru Ohsawa; Masashi Ikutani; Satoshi Takaki; Kensaku Sakamoto; Miki Hara-Yokoyama; Mikako Shirouzu; Kiyoshi Takatsu; Shigeyuki Yokoyama
Journal:  Protein Sci       Date:  2012-04-23       Impact factor: 6.725

4.  The role of interchain heterodisulfide formation in activation of the human common beta and mouse betaIL-3 receptors.

Authors:  Shamaruh Mirza; Jinglong Chen; James M Murphy; Ian G Young
Journal:  J Biol Chem       Date:  2010-06-01       Impact factor: 5.157

5.  Slow-dissociation effect of common signaling subunit beta c on IL5 and GM-CSF receptor assembly.

Authors:  Tetsuya Ishino; Adrian E Harrington; Meirav Zaks-Zilberman; Jeffery J Scibek; Irwin Chaiken
Journal:  Cytokine       Date:  2008-02-21       Impact factor: 3.861

6.  Interleukin-5 receptor subunit oligomerization and rearrangement revealed by fluorescence resonance energy transfer imaging.

Authors:  Meirav Zaks-Zilberman; Adrian E Harrington; Tetsuya Ishino; Irwin M Chaiken
Journal:  J Biol Chem       Date:  2008-03-07       Impact factor: 5.157

7.  Comparative modelling of protein structure and its impact on microbial cell factories.

Authors:  Nuria B Centeno; Joan Planas-Iglesias; Baldomero Oliva
Journal:  Microb Cell Fact       Date:  2005-06-30       Impact factor: 5.328

Review 8.  Interleukin-5 in the Pathophysiology of Severe Asthma.

Authors:  Corrado Pelaia; Giovanni Paoletti; Francesca Puggioni; Francesca Racca; Girolamo Pelaia; Giorgio Walter Canonica; Enrico Heffler
Journal:  Front Physiol       Date:  2019-12-17       Impact factor: 4.566

Review 9.  Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.

Authors:  Corrado Pelaia; Alessandro Vatrella; Andrea Bruni; Rosa Terracciano; Girolamo Pelaia
Journal:  Drug Des Devel Ther       Date:  2018-03-21       Impact factor: 4.162

Review 10.  Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.

Authors:  Corrado Pelaia; Cecilia Calabrese; Alessandro Vatrella; Maria Teresa Busceti; Eugenio Garofalo; Nicola Lombardo; Rosa Terracciano; Girolamo Pelaia
Journal:  Biomed Res Int       Date:  2018-05-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.